Preclinical Modeling(临床前建模)研究综述
Preclinical Modeling 临床前建模 - For preclinical modeling, the growth rate of cholangiocyte organoids (cho-orgs) was harmonized. [1] Preclinical modeling with diverse types of lymphomas and deep characterization are important for the drug discovery of new lymphoma treatments. [2] Experimentation on these embryo models can lead to a better understanding of the mechanisms of development and offers opportunities for functional genomic studies of disease-causing mechanisms, identification of therapeutic targets, and preclinical modeling of advanced therapeutics for precision medicine. [3] 0 × 108/kg in the presence of cyclosporine (CSA) and mycophenolate mofetil (MMF) with no dose-limiting toxicities, subsequent patients were to receive iTregs in the presence of sirolimus/MMF that favors Foxp3 stability based on preclinical modeling. [4] Despite extensive efforts to characterize hNSCs and end-stage GBM at bulk and single-cell levels, the de novo gliomagenic path from hNSCs is largely unknown due to technical difficulties in early-stage sampling and preclinical modeling. [5] Both rhesus‐ and human‐specific agents appear appropriate for preclinical modeling of clinical RATG use. [6] The molecular pathogenesis of pyelonephritis is less well characterized, due to previous limitations in preclinical modeling of kidney infection. [7] Genomic analyses from patient biopsies combined with preclinical modeling have pointed to loss of tumor suppressors RB1 and TP53 as key facilitators of lineage plasticity. [8] Therefore, EOs with proven efficacy in both types of pain were corroborated by methodologically consistent studies, like the EO of bergamot, which should be studied in clinical trials to enhance the translational impact of preclinical modeling on clinical pain research. [9] RECENT FINDINGS Across multiple pediatric cancer types, dependencies on a number of key metabolic pathways have emerged through study of patient tissue samples and preclinical modeling. [10] The translation of clinical risk at the molecular level and the ability to predict early events are of key importance for individualized patient management and preclinical modeling in order to advance therapeutic options. [11] Preclinical modeling has shown that costimulation of natural killer (NK) cells via the Fc receptor and the IL12 receptor promotes NK-cell–mediated ADCC and production of cytokines. [12] Our study demonstrates a translational framework for treating rapidly evolving tumors through preclinical modeling and single-cell analyses. [13] Advances in preclinical modeling and single-cell genomics will also accelerate novel discoveries for effective treatment of IPF. [14] Our study demonstrates a translational framework for treating rapidly evolving tumors through preclinical modeling and single-cell analyses. [15]对于临床前建模，胆管细胞类器官 (cho-orgs) 的生长速率是一致的。 [1] 具有不同类型淋巴瘤和深度表征的临床前建模对于发现新的淋巴瘤治疗药物非常重要。 [2] 对这些胚胎模型进行实验可以更好地理解发育机制，并为致病机制的功能基因组研究、治疗靶点的识别以及精准医学先进疗法的临床前建模提供机会。 [3] 在没有剂量限制性毒性的环孢素 (CSA) 和霉酚酸酯 (MMF) 存在下 0 × 108/kg，随后的患者将在西罗莫司/MMF 存在下接受 iTregs，这有利于基于临床前建模的 Foxp3 稳定性。 [4] 尽管在大量和单细胞水平上对 hNSCs 和终末期 GBM 进行了广泛的研究，但由于早期取样和临床前建模的技术困难，hNSCs 的从头胶质瘤形成途径在很大程度上是未知的。 [5] 恒河猴和人类特异性药物似乎都适用于临床 RATG 使用的临床前建模。 [6] 由于先前对肾脏感染的临床前建模存在局限性，肾盂肾炎的分子发病机制尚不清楚。 [7] 来自患者活检的基因组分析与临床前建模相结合，表明肿瘤抑制因子 RB1 和 TP53 的缺失是谱系可塑性的关键促进因素。 [8] 因此，在两种类型的疼痛中均已证明有效的 EO 已通过方法学一致的研究得到证实，例如佛手柑的 EO，应在临床试验中对其进行研究，以增强临床前建模对临床疼痛研究的转化影响。 [9] 最近的发现 在多种儿科癌症类型中，通过对患者组织样本的研究和临床前建模，已经出现了对许多关键代谢途径的依赖。 [10] 在分子水平上转化临床风险和预测早期事件的能力对于个体化患者管理和临床前建模以推进治疗选择至关重要。 [11] 临床前模型表明，通过 Fc 受体和 IL12 受体共同刺激自然杀伤 (NK) 细胞可促进 NK 细胞介导的 ADCC 和细胞因子的产生。 [12] 我们的研究展示了一个通过临床前建模和单细胞分析来治疗快速发展的肿瘤的转化框架。 [13] 临床前建模和单细胞基因组学的进展也将加速发现有效治疗 IPF 的新发现。 [14] 我们的研究展示了一个通过临床前建模和单细胞分析来治疗快速发展的肿瘤的转化框架。 [15]